Abpro Holdings Receives Nasdaq Delisting Notice; Trading Suspension Imminent
ABP is trading near its 52-week low of $0.517 (0.6% above the low).
Summary
Abpro Holdings, Inc. announced it received a delisting notice from Nasdaq, with trading set to be suspended on February 23, 2026, due to non-compliance with minimum equity standards.
Key Events · Corporate Governance and Compliance · ABP
-
Nasdaq Delisting Notice Received
On February 18, 2026, Abpro Holdings received written notification from the Nasdaq Hearings Panel stating its securities will be delisted from Nasdaq.
-
Trading Suspension Imminent
Trading of the company's securities on Nasdaq will be suspended at the open of trading on February 23, 2026.
-
Failure to Meet Equity Standard
The delisting is a result of the company's failure to demonstrate compliance with Nasdaq Listing Rule 5550(b)(1) (minimum equity standard) by the February 16, 2026 deadline.
-
Company Plans to Appeal
Abpro Holdings expects to appeal the Panel's decision to the Nasdaq Listing and Hearing Review Council within 15 days.
Analysis · ABP · Life Sciences
Abpro Holdings, a micro-cap life sciences company, has received a formal delisting notice from Nasdaq due to its failure to meet the minimum equity standard. This is a critical negative development, as delisting typically leads to significantly reduced liquidity, transparency, and investor interest, making it harder for the company to raise capital or attract new investors. While the company plans to appeal, the imminent trading suspension on Nasdaq and a potential move to the OTC Pink Market signal severe challenges. This event follows a series of recent negative disclosures, including director resignations and a CEO loan to cover insurance, indicating ongoing financial distress. Investors should be aware of the heightened risks associated with trading on the OTC Pink Market, including increased volatility and limited information.
At the time of this filing, ABP was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.52 to $29.97. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.